A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds
| Status: | Withdrawn |
|---|---|
| Conditions: | Gastrointestinal, Podiatry, Diabetes |
| Therapuetic Areas: | Endocrinology, Gastroenterology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
This research project is testing a product called AmnioClear™ which is an amniotic membrane
graft processed for Liventa Bioscience formerly AFCell Medical. AmnioClear™ allograft human
amniotic membrane is regulated solely under section 361 of the Public Health Service Act.
The purpose of the study is to see if this treatment works to accelerate the healing time of
chronic wounds.
graft processed for Liventa Bioscience formerly AFCell Medical. AmnioClear™ allograft human
amniotic membrane is regulated solely under section 361 of the Public Health Service Act.
The purpose of the study is to see if this treatment works to accelerate the healing time of
chronic wounds.
Inclusion Criteria:
- Stable Type I or II diabetes mellitus
- At least one chronic diabetic ulcer
- Full-thickness ulcer size from 1-8 cm2.
Exclusion Criteria:
- Concurrent use of corticosteroids, NSAIDs immuno-suppressive or cytotoxic agents
- Bleeding disorders
- Ulcer with muscle, tendon, capsule or bone involvement
We found this trial at
1
site
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
Click here to add this to my saved trials
